Pfizer says late-stage coronavirus vaccine study shows moderate side effects




  • In Business
  • 2020-09-16 02:33:43Z
  • By Reuters
Pfizer says late-stage coronavirus vaccine study shows moderate side effects
Pfizer says late-stage coronavirus vaccine study shows moderate side effects  

By Manas Mishra

(Reuters) - Pfizer Inc said on Tuesday participants were showing mild-to-moderate side effects when given either the company's experimental coronavirus vaccine or a placebo in an ongoing late-stage study.

Over 12,000 study participants had received a second dose of the vaccine, Pfizer executives said on an investor conference call.

The company has enrolled more than 29,000 people in its 44,000-volunteer trial to test the experimental COVID-19 vaccine it is developing with German partner BioNTech.

Pfizer said it was continuously scrutinizing the safety and tolerability of the vaccine in its study.

An independent data monitoring committee could recommend pausing the study at any time, but has not done so till date, the company said.

The comments follow rival AstraZeneca's COVID-19 vaccine trials being put on hold worldwide on Sept. 6 after a serious side effect was reported in a volunteer in Britain.

AstraZeneca's trials resumed in Britain and Brazil on Monday following the green light from British regulators, but remain on hold in the United States.

COMMENTS

More Related News

Exclusive: FDA widens U.S. safety inquiry into AstraZeneca coronavirus vaccine - sources
Exclusive: FDA widens U.S. safety inquiry into AstraZeneca coronavirus vaccine - sources
  • US
  • 2020-09-30 21:39:48Z

The U.S. Food and Drug Administration has broadened its investigation of a serious illness in AstraZeneca Plc's COVID-19 vaccine study and will look at data from earlier trials of similar vaccines developed by the same scientists, three sources familiar with the details told Reuters. AstraZeneca's large, late-stage U.S. trial has remained on hold since Sept. 6, after a study participant in Britain fell ill with what was believed to be a rare spinal inflammatory disorder called transverse myelitis. The widened scope of the FDA probe raises the likelihood of additional delays for what has been one of the most advanced COVID-19 vaccine candidates in development.

SIGN UP: Learn the latest on the road ahead for a COVID-19 shot at our live event
SIGN UP: Learn the latest on the road ahead for a COVID-19 shot at our live event

Learn the latest on coronavirus vaccines with bioethicist Art Caplan and infectious-disease experts Maria Elena Bottazzi and Dr. William Haseltine.

Neanderthal genes linked to severe COVID-19; Mosquitoes cannot transmit the coronavirus
Neanderthal genes linked to severe COVID-19; Mosquitoes cannot transmit the coronavirus
  • US
  • 2020-09-30 18:49:42Z

A group of genes passed down from extinct human cousins is linked with a higher risk for severe COVID-19, researchers say. When they compared the genetic profiles of about 3,200 hospitalized COVID-19 patients and nearly 900,000 people from the general population, they found that a cluster of genes on chromosome 3 inherited from Neanderthals who lived more than 50,000 years ago is linked with 60% higher odds of needing hospitalization. People with COVID-19 who inherited this gene cluster are also more likely to need artificial breathing assistance, coauthor Hugo Zeberg of the Max Planck Institute for Evolutionary Anthropology said in a news release.

What you need to know about the coronavirus right now
What you need to know about the coronavirus right now
  • US
  • 2020-09-30 10:54:24Z

Results from an early safety study of Moderna's coronavirus vaccine candidate in older adults showed that it produced virus-neutralizing antibodies at levels similar to those seen in younger adults, with side effects roughly on par with high-dose flu shots. The findings are reassuring because immunity tends to weaken with age, Dr. Evan Anderson, one of the study's lead researchers, said in a phone interview. Germany's CureVac said it has started a mid-stage study testing its experimental vaccine and plans to begin a decisive global trial with about 30,000 volunteers in the fourth quarter.

Russia to supply Egypt with COVID-19 vaccine in expansion push
Russia to supply Egypt with COVID-19 vaccine in expansion push
  • US
  • 2020-09-30 07:03:13Z

Russia has clinched a deal with Egypt to supply it with 25 million doses of its Sputnik V coronavirus vaccine, as Moscow seeks to take a leading global role in fighting the pandemic. Russia's sovereign wealth fund, RDIF, said on Wednesday it had agreed to supply the vaccine doses to Egypt via Pharco, which it described as one of the country's leading pharmaceutical groups. "The agreement between RDIF and Pharco will help Egypt obtain an efficient and safe vaccine, Sputnik V, for almost 25% of its population," RDIF chief executive Kirill Dmitriev said in a statement.

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: Business